Pierre Tambourin
Director Ejecutivo en Société d'Economie Mixte Genopole SAEM .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Jean-François Floch | M | - |
BioRéalités SAS
BioRéalités SAS Pharmaceuticals: MajorHealth Technology BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006. | 17 años |
Geneviève Blanc | F | 60 |
BioRéalités SAS
BioRéalités SAS Pharmaceuticals: MajorHealth Technology BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006. | - |
Dominique Joubert | M | - |
BioRéalités SAS
BioRéalités SAS Pharmaceuticals: MajorHealth Technology BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006. | 17 años |
Frederic Hollande | M | - |
BioRéalités SAS
BioRéalités SAS Pharmaceuticals: MajorHealth Technology BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006. | 17 años |
Christophe Carniel | M | 58 |
BioRéalités SAS
BioRéalités SAS Pharmaceuticals: MajorHealth Technology BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006. | - |
Karine Chorro | F | - |
BioRéalités SAS
BioRéalités SAS Pharmaceuticals: MajorHealth Technology BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006. | - |
Jean-Luc Bernard | M | - |
BioRéalités SAS
BioRéalités SAS Pharmaceuticals: MajorHealth Technology BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006. | - |
Jocelyn Olive | M | - |
BioRéalités SAS
BioRéalités SAS Pharmaceuticals: MajorHealth Technology BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006. | - |
Stéphane Beaudet | M | 52 |
Société d'Economie Mixte Genopole SAEM
Société d'Economie Mixte Genopole SAEM Real Estate DevelopmentFinance Société d'Economie Mixte Genopole SAEM engages in the development of biotechnologies. It specializes in the research of genomics and genetics. The company was founded in 1998 and is headquartered in Evry, France. | 8 años |
Gráfico relacional
Relaciones con varias empresas
Estadísticas
País | Relaciones | % del total |
---|---|---|
Francia | 9 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Pierre Tambourin
- Red Personal